Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AbbVie’s Drug Rova-T Shows Promise — But Not Enough — in SCLC

By Stephanie Guzowski | June 7, 2016

Small-cell lung cancer of a human, photomicrograph panorama as seen under the microscope, 200x zoom.

Experimental drug rovalpituzumab tesirine (Rova-2) was effective in treating patients with advanced small cell lung cancer (SCLC), according to data from a first-in-human clinical trial, presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

And although the results are preliminary, that’s good news: Rova-2 could be the first treatment to make an impact on SCLC, which kills approximately 60,000 patients in the U.S. each year. There has been no change in survival rates for SCLC since the 1970s, according to Charles Rudin, a Memorial Sloan Kettering oncologist who led the study.

Rova-T targets the delta-like 3 (DLL3) protein, which is overexpressed in about two-thirds of SCLC tumors. The antibody-drug conjugate binds to DLL3 on the surface of tumor cells killing the detected cells, while salvaging normal tissue. Significantly, patients with the highest levels of DLL3 in their tumors responded best to the treatment.

“Rova-T seems to be the first targeted therapy to show efficacy in SCLC, and we may have identified DLL3 as the first predictive biomarker in this disease,” said Rudin.

The clinical trial included 74 patients with SCLC that had progressed after at least one course of therapy. Of 60 evaluable patients receiving Rova-T, 68 percent experienced disease stabilization and 18 percent experienced tumor shrinkage. And in the 26 patients whose tumors overexpressed DLL3, 39 percent responded to the therapy.

That puts the median overall survival rate at 5.8 months with 32 percent of the patients alive after a year of treatment. But that’s a month longer — 5.8-month median survival versus the 4.7-month historical average — according to Forbes’s Matthew Herper, who said, “Many on Wall Street are likely to find that 1-month survival benefit disappointing.” What’s more, Rova-T’s median survival was less than a combination of Bristol-Myers Squibb’s Opdivo and Yervoy, which showed 7.7 months median survival.

And that’s significant considering the price AbbVie paid: $5.8 billion upfront —and $4 billion reserved for drug approvals and sales — for the biotech startup, Stemcentrx, which manufactures Rova-T.

Next up will be confirmation in larger trials: Rova-T will be tested in a 154-patient study that will include patients with high levels of DLL3. Combination therapies of Rova-T and Opdivo are also being considered.

Side effects of Rova-T included fluid build-up in the heart or lungs, low platelet count, and skin reactions.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE